MedTrace Logo

Real World Study of Effectiveness of Sunitinib or Sorafenib to Chinese Unresectable Locally Advanced or Metastatic PRCC

NCT07024680 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2025-11-18

No results posted yet for this study

Summary

This is a multi-center, observational, retrospective study designed to characterize the effectiveness and safety of sunitinib or sorafenib monotherapy in the treatment of Chinese adult patients with unresectable and locally advanced or metastatic PRCC, who have not received any prior systemic anticancer therapy in the metastatic setting. Electronic medical record (EMR) data of patients with 1L sunitinib or sorafenib monotherapy will be screened from Grade-A Tertiary hospitals in China. The study period is from 1st September 2007 to 31st December 2024.

Conditions

  • Papillary Renal Cell Carcinoma

Interventions

OTHER

Observational, None intervention

Observational, None intervention

Sponsors & Collaborators

Principal Investigators

  • DingWei Ye, Postdoctoral · Fudan University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-31
Primary Completion
2026-07-14
Completion
2026-07-14

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07024680 on ClinicalTrials.gov